Pioneering diagnostic system to be showcased at IFCPC World Congress

Tuesday 4th April 2017

A pioneering diagnostic system that is having a significant impact on the global changing clinical pathway for cervical cancer will be on display at the International Federation of Cervical Pathology and Colposcopy (IFCPC) World Congress.

Developed by UK based Zilico Ltd, ZedScan™ is a portable, handheld device that uses patented Electrical Impedance Spectroscopy (EIS) to detect the development of pre-cancerous abnormalities of the cervix, known as cervical intraepithelial neoplasia (CIN).

The innovative system not only removes subjectivity and increases accuracy, but it also helps clinicians manage growing colposcopy referrals generated by the introduction of primary HPV testing.

In a recent review of over 1500 women referred to an NHS colposcopy clinic, the adoption of ZedScan resulted in a significant increase in disease detection and improvements in clinical performance.

The patient case study revealed a 13% increase in detection of high-grade disease (HGCIN) across all patients, with 50% increase reported in women with low-grade cytology. In 92% of these cases, disease was confirmed with a single biopsy.

If rolled out across the UK, this would equate to an additional 200 women being identified with HGCIN every week, or approximately 10,000 women each year who can therefore be diagnosed and treated much earlier. Thus preventing disease from developing.

Performance was not impacted by the hrHPV genotype with increased detection in both HPV16 and non 16 hrHPV positive women.

Cervical cancer is the 7th most common disease globally, and the third most prevalent in woman. The disease is caused by the persistent high-risk human papillomavirus (HPV) infection, which triggers changes in the cervical cells.

Each year it is estimated that 12,820 women in the United States will be diagnosed with cervical cancer and there are 4,210 deaths from the disease.

Although colposcopy is an important method in detecting cervical cancer, in practice, the procedure has not drastically changed over the last 90 years, and diagnosis depends on the subjective assessment of visual indicators by the clinician. An objective assessment will help clinicians to better manage patients and help avoid unnecessary biopsies, treatments and repeat follow-up appointments.

Sameer Kothari, Chief Executive of Zilico Ltd, said: “ZedScan is now used in many hospitals across the globe as an adjunct to the current diagnostic process to offer a more accurate diagnosis in real time and assist clinicians with improved patient management.

“Colposcopy referrals are expected to increase dramatically following the introduction of HPV screening and ZedScan can provide a cost effective means to accommodate this growth. It can also increase compliance with hospital guidelines for performance and waiting times. We are very excited to be able to showcase the system at the IFCPC World Congress.”

Taking place in Orlando, Florida, the IFCPC is taking place from 4 – 7 April and throughout the show, Zilico will be located in booth 310.

For more information:



Editor’s Notes

More information about Zilico Ltd

Zilico's product portfolio is centred on its patented Electrical Impedance Spectroscopy (EIS) technology, applicable to a wide range of neoplastic conditions. The company prides itself on creating innovative technology that removes subjectivity, increases accuracy and delivers results in real-time. Zilico's head office is located in Manchester, UK with a subsidiary office in Sheffield. Manufacturing and R&D functions are also carried out in the UK and Zilico achieved ISO 13485 accreditation in 2013.

For more information about Zilico, please contact:
Zilico Ltd, tel: +44 161 826 7840; email: or visit

For press enquiries, please contact:

Julia Price, tel: +44 7737 864 878; e-mail: